The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.

Intel stock surges 90%, see how Nvidia partnership, vPro upgrades, and ASP growth could offset INTC's margin pressures.

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable ...

SAVANNAH, GA, UNITED STATES, July 4, 2025 /EINPresswire.com/ -- Stellar Market Research examines the growth rate of the Intraosseous Infusion Devices Market during ...

Intraosseous Infusion Devices revenue is expected to grow by CAGR 6.2% from 2025 to 2032 and reach nearly USD 8.79 Bn. In 2032. From ER to EMS, intraosseous infusion is changing how we deliver urgent ...

Intraosseous Infusion Devices Market is estimated to be valued at USD 1,112.1 Mn in 2025 and is expected to reach USD 1,607. Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.4% from ...

The global market for intraosseous infusion devices is witnessing a significant surge, with demand expected to skyrocket from USD 4.4 billion in 2023 to an impressive USD 8.6 billion by 2033. This ...

Two new therapies became available in January at Catholic Health that delay the progression of two chronic diseases. Buffalo-area hospitals can lay claim to a series of innovations over the last 50 ...